NCT02169596View on ClinicalTrials.gov

Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Acute Coronary Syndome

Interventions

DRUG

Ticagrelor

Blood tests taken for flow cytometry

OTHER

EndoPAT - endothelial assessment

Trial Locations (1)

HU16 5JQ

Castle Hill Hospital (Hull and east Yorkshire Hospitals NHS Trust), Cottingham

All Listed Sponsors

lead

Hull University Teaching Hospitals NHS Trust

OTHER_GOV

NCT02169596 - Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide? | Biotech Hunter | Biotech Hunter